RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

30 Aug 24

Updated

13 Dec 25

Views

126

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-6.9%

7D

-6.1%

Loading

1Y

-6.9%

7D

-6.1%

You can edit this narrative until Dec 14 5:10 PM. Then, changes will post as Updates.

Author's Valuation

US$91.7122.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 13 Dec 25

Fair value Decreased 0.85%

RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance

Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.

Shared on 28 Nov 25

Fair value Increased 6.73%

RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance

Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.

Shared on 13 Nov 25

Fair value Increased 7.57%

RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings

RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.

Shared on 30 Oct 25

Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.

Shared on 15 Oct 25

Fair value Increased 1.62%

RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.

Shared on 19 Sep 25

Fair value Increased 2.40%

RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.

Shared on 04 Sep 25

Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.

Shared on 07 May 25

Fair value Increased 7.93%

Shared on 30 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 4.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 0.83%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 3.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Increased 7.75%

AnalystConsensusTarget has decreased revenue growth from 7.3% to 6.6%.

AnalystConsensusTarget Fair Value

US$91.71

22.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

9.82%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$110.11m

Earnings '28

x

88.67x

PE Ratio '28

=

US$9.76b

Market Cap '28

US$9.76b

Market Cap '28

/

87.26m

No. shares '28

=

US$111.88

Share Price '28

US$111.88 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$91.44

Fair Value '25